KRAS Inhibitor Resistance in <i>MET</i> -Amplified <i>KRAS</i> G12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms
Shinichiro Suzuki(Kindai University), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Kazuko Sakai(Kindai University Sakai Hospital), Toshiyuki Takehara(Kindai University), Hidetoshi Hayashi(Kindai University), Kimio Yonesaka(Kindai University), Koji Haratani(Dana-Farber Cancer Institute), Junko Tanizaki(Kindai University Sakai Hospital), Takeshi Teramura(Kindai University Hospital), Ryoji Kato(Kindai University), Kazuto Nishio(Kindai University Sakai Hospital), Hitomi Sakai(Kindai University Hospital), Hisato Kawakami(Tohoku University)
Cited by 105
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
|Journal of Clinical Oncology|2011|1.6k